Akari Therapeutics (AKTX) 6-K/A 14 Apr 17 2016 Q2 Current report (foreign) (amended) Financial data

Document And Entity Information

Document And Entity Information	6 Months Ended
	Jun. 30, 2016shares
Document Information [Line Items]
Entity Registrant Name	Akari Therapeutics Plc
Entity Central Index Key	1,541,157
Document Type	6-K
Amendment Flag	false
Document Period End Date	Jun. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q2
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Trading Symbol	AKTX
Entity Common Stock, Shares Outstanding	0

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Current Assets:
Cash and cash equivalents	$ 9,662,454	$ 68,919,995
Short-term investments	46,120,172	0
Prepaid expenses and other current assets	1,580,915	728,126
Receivable from related party	10,502	10,366
Total Current Assets	57,374,043	69,658,487
Restricted cash	142,114	142,079
Property and equipment, net	71,236	40,513
Patent acquisition costs, net	45,770	52,483
Total Assets	57,633,163	69,893,562
Current Liabilities:
Accounts payable	1,917,984	4,320,588
Accrued expenses	360,679	408,222
Liabilities related to options and warrants	14,715,371	16,396,158
Total Current Liabilities	16,994,034	21,124,968
Other long-term liability	55,131	49,069
Total liabilities	17,049,165	21,174,037
Commitments and Contingencies
Shareholders’ Equity:
Share capital of GBP £0.01 par value Authorized: 5,000,000,000 shares; issued and outstanding: 1,177,693,383 at June 30, 2016 and December 31, 2015	18,340,894	18,340,894
Additional paid-in capital	88,668,352	87,018,764
Accumulated other comprehensive (loss) income	(191,873)	156,480
Accumulated deficit	(66,233,375)	(56,796,613)
Total Shareholders’ Equity	40,583,998	48,719,525
Total Liabilities and Shareholders’ Equity	$ 57,633,163	$ 69,893,562

CONDENSED CONSOLIDATED BALANCE3

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - £ / shares	Jun. 30, 2016	Dec. 31, 2015
Common stock, par value	£ 0.01	£ 0.01
Common stock, shares authorized	5,000,000,000	5,000,000,000
Common stock, shares issued	1,177,693,383	1,177,693,383
Common stock, shares outstanding	1,177,693,383	1,177,693,383

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Operating Expenses:
Research and development costs	$ 5,443,105	$ 1,001,180	$ 6,942,648	$ 2,556,130
General and administrative expenses	2,076,795	310,833	4,429,230	410,512
Total Operating Expenses	7,519,900	1,312,013	11,371,878	2,966,642
Loss from Operations	(7,519,900)	(1,312,013)	(11,371,878)	(2,966,642)
Other Income (Expense):
Interest income	17,307	0	48,111	0
Changes in fair value of option/warrant liabilities	976,452	0	1,680,787	0
Foreign currency exchange gains/(losses)	87,210	(22)	241,641	(37,623)
Interest expense	0	(2,613)	0	(7,169)
Other expenses	(12,447)	(26,120)	(35,423)	(26,120)
Total Other Income (Expense)	1,068,522	(28,755)	1,935,116	(70,912)
Net Loss	(6,451,378)	(1,340,768)	(9,436,762)	(3,037,554)
Other Comprehensive Income (Loss):
Foreign Currency Translation Adjustment	(155,409)	21,219	(348,353)	45,074
Comprehensive Loss	$ (6,606,787)	$ (1,319,549)	$ (9,785,115)	$ (2,992,480)
Loss per common share (basic and diluted)	$ (0.005)	$ (0.002)	$ (0.008)	$ (0.004)
Weighted average common shares (basic and diluted)	1,177,693,383	722,345,600	1,177,693,383	722,345,600

CONDENSED CONSOLIDATED STATEME5

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY - 6 months ended Jun. 30, 2016 - USD ($)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]
Beginning Balance at Dec. 31, 2015	$ 48,719,525	$ 18,340,894	$ 87,018,764	$ 156,480	$ (56,796,613)
Beginning Balance (in shares) at Dec. 31, 2015		1,177,693,383
Stock-based compensation	1,622,211	$ 0	1,622,211	0	0
Dissolution of subsidiary	27,377	0	27,377	0	0
Foreign Currency Translation Loss	(348,353)	0	0	(348,353)	0
Net Loss	(9,436,762)	0	0	0	(9,436,762)
Ending Balance at Jun. 30, 2016	$ 40,583,998	$ 18,340,894	$ 88,668,352	$ (191,873)	$ (66,233,375)
Ending Balance (in shares) at Jun. 30, 2016		1,177,693,383

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Cash Flows from Operating Activities:
Net loss	$ (9,436,762)	$ (3,037,554)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	18,785	1,631
Stock-based compensation	1,622,211	0
Changes in fair value of the liability for options and warrants	(1,680,787)	0
Foreign currency exchange gains	(356,954)	0
Increase in assets:
Prepaid expenses and other current assets	(852,418)	(112,610)
Increase (decrease) in liabilities:
Accounts payable and accrued expenses	(2,452,151)	462,512
Other liabilities	6,062	0
Total adjustments	(3,695,252)	351,533
Net Cash Used in Operating Activities	(13,132,014)	(2,686,021)
Cash Flows from Investing Activities:
Purchase of property and equipment	(47,980)	0
Purchase of short-term investments	(46,120,172)	0
Net Cash Used in Investing Activities	(46,168,152)	0
Cash Flows from Financing Activities:
Repayment of shareholder loans	0	(508,713)
Net Cash Used in Financing Activities	0	(508,713)
Effect of Exchange Rates on Cash and Cash Equivalents	42,625	68,710
Net Decrease in Cash and Cash Equivalents	(59,257,541)	(3,126,024)
Cash and Cash Equivalents, beginning of period	68,919,995	3,327,468
Cash and Cash Equivalents, end of period	9,662,454	201,444
Cash paid during the period for:
Interest	$ 0	$ 2,636

Nature of Business

Nature of Business	6 Months Ended
	Jun. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations [Text Block]	NOTE 1 - Nature of Business Akari Pharmaceuticals, Plc, (the “Company” or “Akari”), formerly Celsus Therapeutics Plc (“Celsus”), is incorporated in the United Kingdom. The Company is a clinical stage biotechnology company, and is focused on developing anti-complement and anti-inflammatory molecules as treatments for a wide range of rare and orphan conditions in the autoimmune and inflammatory diseases sectors. On September 18, 2015, Celsus Therapeutics Plc completed its acquisition of all of the capital stock of Volution Immuno Pharmaceuticals SA (“Volution”), from RPC Pharma Limited (“RPC”), Volution’s sole shareholder, in exchange for ordinary shares, par value £ 0.01 In connection with the consummation of the Acquisition, Celsus issued an aggregate of 722,345,600 92.85 91.68 The Company, as defined in the accompanying notes to the condensed consolidated financial statements, refers to Volution prior to the Acquisition and Akari subsequent to the completion of the Acquisition. In addition, on September 18, 2015, the Company completed a private placement of an aggregate of 3,958,811 395,881,100 75 18.945 33.3 Volution was originally incorporated in Switzerland as a private limited company and commenced business on October 9, 2013. On October 23, 2013, Varleigh Immuno Pharmaceuticals Ltd (“Varleigh”), a UK limited company, transferred certain patent rights to Volution in exchange for a payment of approximately $ 107,000 65,000 On July 3, 2015, the shareholders of Volution exchanged their shares for RPC shares with no changes in individual share ownerships. This qualified as a reorganization. The Company is subject to a number of risks similar to those of clinical stage companies, including dependence on key individuals, uncertainty of product development and generation of revenues, dependence on outside sources of capital, risks associated with clinical trials of products, dependence on third-party collaborators for research operations, need for regulatory approval of products, risks associated with protection of intellectual property, and competition with larger, better-capitalized companies. Successful completion of the Company’s development program and, ultimately, the attainment of profitable operations is dependent upon future events, including obtaining adequate financing to fulfill its development activities and achieving a level of revenues adequate to support the Company’s cost structure. There are no assurances that the Company will be able to obtain additional financing on favorable terms, or at all or successfully market its products.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	NOTE 2 - Summary of Significant Accounting Policies All intercompany transactions have been eliminated. The reporting currency of the Company is U.S. Dollars. The Company translated its non-U.S. operations’ assets and liabilities denominated in foreign currencies into U.S. dollars at current rates of exchange as of the balance sheet date and income and expense items at the average exchange rate for the reporting period. Translation adjustments resulting from exchange rate fluctuations are recorded as foreign currency translation adjustments, a component of accumulated other comprehensive (loss) income. Gains or losses from foreign currency transactions are included in foreign currency exchange gains (losses). The Company’s liabilities related to options and warrants are warrants related to equity and debt financing rounds and options related to RPC and are recognized on the balance sheet at their fair value, with changes in the fair value accounted for in the statements of comprehensive loss and included in change in fair value of option/warrant liabilities. Years Computers, peripheral, and scientific equipment 3 Office furniture and equipment 4 22 The Company expenses costs associated with maintaining and defending patents subsequent to their issuance in the period incurred. earnings (loss) per common share is computed by dividing net income (loss) available to common shareholders by the sum of (1) the weighted-average number of Ordinary Shares outstanding during the period, (2) the dilutive effect of the assumed exercise of options and warrants using the treasury stock method and (3) the dilutive effect of other potentially dilutive securities. Balance January 1, 2016 $ 156,480 Net current period other comprehensive loss (348,353) Balance June 30, 2016 $ (191,873) In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers” (“ASU 2014-09”), which supersedes nearly all existing revenue recognition guidance under GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing GAAP. On July 9, 2015, the FASB voted to defer the effective date by one year to December 15, 2017 for interim and annual reporting periods beginning after that date. Early adoption of ASU 2014-09 is permitted but not before the original effective date (annual periods beginning after December 15, 2016). When effective, ASU 2014-09 prescribes either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients; or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). We are currently evaluating the impact of our pending adoption of ASU 2014-09 on our condensed consolidated financial statements and have not yet determined the method by which we will adopt the standard. In February 2016, the FASB issued ASU No. 2016-02, Leases In March 2016, the FASB issued ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting

Reverse Acquisition

Reverse Acquisition	6 Months Ended
	Jun. 30, 2016
Business Combinations [Abstract]
Business Combination Disclosure [Text Block]	NOTE 3 – Reverse Acquisition The Company completed its Acquisition as discussed in Note 1. Based on the terms of the Acquisition and since the Volution securityholders owned approximately 91.68 The acquisition consideration for accounting purposes consisted of Ordinary Shares and the fair value of vested options and warrants issued by Celsus that were outstanding at the date of the Acquisition immediately prior to closing. Assets and liabilities of Celsus were measured at fair value and added to the assets and liabilities of Volution, and the historical results of operations of Volution were reflected in the results of operations of the Company following the Acquisition. In connection with the consummation of the Acquisition, the Company issued an aggregate of 722,345,600 The purchase price for Celsus on September 18, 2015, the closing date of the Acquisition, was as follows: Fair value of Celsus Ordinary Shares outstanding $ 20,034,625 (a) Fair value of Celsus share options 277,461 (2,516,690 options) Fair value of Celsus warrants 27,054 (1,782,246 warrants) Total purchase price $ 20,339,140 (a) computed by multiplying 55,636,283 Ordinary Shares of Celsus at Acquisition by the closing price on September 18, 2015, of $0.3601. Allocation of Purchase Consideration Under the acquisition method of accounting, the total purchase price was allocated to tangible and identifiable intangible assets acquired and liabilities assumed of Celsus on the basis of their estimated fair values as of the transaction closing date on September 18, 2015. The excess of the total purchase price over the fair value of assets acquired and liabilities assumed was allocated to excess consideration. The following table summarizes the allocation of the purchase consideration to the assets acquired and liabilities assumed based on their fair values as of September 18, 2015: Cash and cash equivalents $ 1,410,577 Restricted cash 142,079 Prepaid expenses and other assets acquired 1,672,028 Excess consideration 19,283,280 Liabilities related to options and warrants (1,800,154) Other assumed liabilities (368,670) Total $ 20,339,140 The Company believes that the historical values of Celsus’s current assets and current liabilities approximate fair value based on the short-term nature of such items. Excess consideration is calculated as the difference between the fair value of the consideration expected to be realized and the values assigned to the identifiable tangible and intangible assets acquired and liabilities assumed. The Company recorded this non-cash charge in the statements of comprehensive loss during the year ended December 31, 2015 due to the fact that goodwill could not be justified and was considered fully impaired.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2016
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	NOTE 4 – Fair Value Measurements Fair value of financial instruments: The estimated fair value of financial instruments has been determined by the Company using available market information and valuation methodologies. Considerable judgment is required in estimating fair values. Accordingly, the estimates may not be indicative of the amounts the Company could realize in a current market exchange. The carrying amounts of cash and cash equivalents, short-term investments, receivable from related party, restricted cash, accounts payable and accrued expenses approximate their fair value due to the short-term maturity of such instruments. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. As a basis for considering such assumptions, ASC 820, “Fair Value Measurements and Disclosures” establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value: Level 1 - quoted prices in active markets for identical assets or liabilities; Level 2 - inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; or Level 3 - unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. June 30, 2016 December 31, 2015 Carrying Fair Carrying Fair Fair Amount Value Amount Value Value $ $ $ $ Levels Liability related to RPC options 14,616,664 14,616,664 15,711,017 15,711,017 3 Liability related to warrants 98,707 98,707 685,141 685,141 3 In accordance with ASC No. 820, the Company measures its liabilities related to options and warrants on a recurring basis at fair value. The liabilities related to options and warrants are classified within Level 3 value hierarchy because the liabilities are based on present value calculations and external valuation models whose inputs include market interest rates, estimated operational capitalization rates, volatilities and illiquidity. Unobservable inputs used in these models are significant. Upon completion of the Acquisition, the Company assumed certain warrants that were issued in connection with several private placements by Celsus and certain investors where it sold Ordinary Shares and warrants. Some of the issued warrants contain non-standard anti-dilution terms and accordingly are recorded as liabilities. As of June 30, 2016, warrants to purchase 5,806,280 share or warrant issuance at less than $0.18945 price share or exercise price per share 98,707 586,434 685,141 The Company accounts for the liability warrants issued in accordance with ASC 815, “Derivatives and Hedging” as a freestanding liability instrument that is measured at fair value at each reporting date, based on its fair value, with changes in the fair values being recognized in the Company’s condensed consolidated statement of comprehensive loss as a change in fair value of option/warrant liabilities. Expected dividend yield 0 % Expected volatility 64.5 % Risk-free interest 0.41 % Expected life 0.76 years In July 2015, the Company raised short-term working capital in the form of loans from shareholders of approximately $ 3 15 15 26 26 3 3 23 As of June 30, 2016, the fair value of the RPC options was $ 14,616,664 1,094,353 15,711,017 June 30 December 31, 2016 2015 Fair value measurements using input type Level 3 Warrants $ 98,707 $ 685,141 RPC options 14,616,664 15,711,017 Liabilities related to stock options and warrants $ 14,715,371 $ 16,396,158 Fair value of liabilities related to stock options and warrants Balance at December 31, 2015 $ 16,396,158 Changes in values of liability related to options and warrants (1,680,787) Balance at June 30, 2016 $ 14,715,371

Shareholders' Equity

Shareholders' Equity	6 Months Ended
	Jun. 30, 2016
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	NOTE 5 – Shareholders’ Equity Share Capital – 5,000,000,000 1,177,693,383 On September 18, 2015, in connection with the Acquisition, 55,636,283 On September 18, 2015, the Company completed a private placement of 395,881,100 75 0.18945 On September 18, 2015, the Company issued 3,830,400 750,000 500,000 Share option plan Upon completion of the Acquisition, the Company assumed the former Celsus 2014 Equity Incentive Plan (the “Plan”). In accordance with the Plan, the number of shares that may be issued upon exercise of options under the Plan, shall not exceed 141,142,420 64,213,556 Weighted average Weighted Weighted remaining average average contractual Aggregate Number exercise grant date term intrinsic of shares price fair value (in years) value Options outstanding as of January 1, 2016 61,362,198 $ 0.34 9.7 $ - Changes during the period: Granted 20,100,000 $ 0.15 $ 0.10 Forfeited (4,533,334) $ 0.18 $ 0.11 Options outstanding as of June 30, 2016 76,928,864 $ 0.30 9.3 $ - Exercisable options as of June 30, 2016 12,797,676 $ 0.42 9.0 $ - Weighted average Number grant date of shares fair value Non-vested options as of December 31, 2015 58,480,181 $ 0.21 Options granted 20,100,000 $ 0.10 Options vested (9,915,659) $ 0.21 Non-vested options forfeited (4,533,334) $ 0.11 Non-vested as of June 30, 2016 64,131,188 $ 0.21 On March 23, 2016, the Company granted 11,000,000 0.141 1,300,000 0.18 7,800,000 0.145 6,500,000 1,300,000 The Company accounts for awards of equity instruments issued to employees and directors under the fair value method of accounting and recognize such amounts in general administrative expenses within its Condensed Consolidated Statements of Comprehensive Loss. The Company measures compensation cost for all share-based awards at fair value on the date of grant and recognize compensation expense in its Condensed Consolidated Statements of Comprehensive Loss using the straight-line method over the service period over which it expects the awards to vest. The Company estimates the fair value of all time-vested options as of the date of grant using the Black-Scholes option valuation model, which was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable. Option valuation models require the input of highly subjective assumptions, including the expected share price volatility, which is calculated based on the historical volatility of the Company’s Ordinary Shares. The Company uses a risk-free interest rate, based on the U.S. Treasury instruments in effect at the time of the grant, for the period comparable to the expected term of the option. Given its limited history with share option grants and exercises, the Company uses the “simplified” method in estimating the expected term, the period of time that options granted are expected to be outstanding, for its grants. June 30, 2016 Expected dividend yield 0 % Expected volatility 74.18%-80.71 % Risk-free interest 1.03%-1.52 % Expected life 5.5-6.25 years Remaining Options Weighted Options contractual outstanding average Weighted exercisable life (years Weighted Exercise as of remaining average as of for average price June contractual exercise June exercisable exercise (range) 30, 2016 life (years) price 30, 2016 options) price $ $ $ 0.14-0.19 21,713,351 9.76 0.16 1,627,185 9.38 0.19 0.32 53,597,347 9.22 0.32 9,915,659 9.22 0.32 0.60-0.75 380,000 7.73 0.71 380,000 7.73 0.71 1.15-1.56 311,500 3.74 1.35 311,500 3.74 1.35 2.00 926,666 7.23 2.00 563,332 7.24 2.00 76,928,864 12,797,676 During the six months ended June 30, 2016, the Company recorded approximately $ 1,622,000 11,057,000 3.2 Warrants to service providers and investors – Number of Exercise Grant date warrants Price Expiration date 2012 warrants 1,383,086 $ 1.72 - $2.25 January 16, 2017-November 30, 2017 2013 warrants 399,160 $ 2.00 January 16, 2018-September 17, 2018 1,782,246

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2016
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	NOTE 6 – Related Party Transactions Accounting Services – 23,000 71,000 Other – 10,502

Earnings Per Share

Earnings Per Share	6 Months Ended
	Jun. 30, 2016
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	NOTE 7 – Earnings Per Share Basic earnings (loss) per Ordinary Share is computed by dividing net income (loss) available to ordinary shareholders by the weighted-average number of Ordinary Shares outstanding during the period. Diluted earnings (loss) per common share is computed by dividing net income (loss) available to ordinary shareholders by the sum of (1) the weighted-average number of Ordinary Shares outstanding during the period, (2) the dilutive effect of the assumed exercise of share options using the treasury stock method, and (3) the dilutive effect of other potentially dilutive securities. Six Months Ended June 30, Earnings per share 2016 2015 Company posted Net loss Net loss Basic weighted average shares outstanding 1,177,693,383 722,345,600 Dilutive effect of Ordinary Share equivalents None None Dilutive weighted average shares outstanding 1,177,693,383 722,345,600 For purposes of the diluted net loss per share calculation, share options and warrants are considered to be potentially dilutive securities and are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive. Therefore, basic and diluted net loss per share was the same for the periods presented due to the Company’s net loss position. The following table shows the number of share equivalents that were excluded from the computation of diluted earnings per share for the respective periods because the effect would have been anti-dilutive: Six-Month Six-Month Period Ended Period Ended June 30, 2016 June 30, 2015 Total share options 76,928,864 - Total warrants-equity classified 1,782,246 - Total warrants-liability classified 5,806,280 - Total share options and warrants 84,517,390 -

Summary of Significant Accoun14

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation
Consolidation, Policy [Policy Text Block]	All intercompany transactions have been eliminated.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency – The reporting currency of the Company is U.S. Dollars. The Company translated its non-U.S. operations’ assets and liabilities denominated in foreign currencies into U.S. dollars at current rates of exchange as of the balance sheet date and income and expense items at the average exchange rate for the reporting period. Translation adjustments resulting from exchange rate fluctuations are recorded as foreign currency translation adjustments, a component of accumulated other comprehensive (loss) income. Gains or losses from foreign currency transactions are included in foreign currency exchange gains (losses).
Use of Estimates, Policy [Policy Text Block]	Use of Estimates –
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements The Company’s liabilities related to options and warrants are warrants related to equity and debt financing rounds and options related to RPC and are recognized on the balance sheet at their fair value, with changes in the fair value accounted for in the statements of comprehensive loss and included in change in fair value of option/warrant liabilities.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents
Investment, Policy [Policy Text Block]	Short-term investments –
Restricted deposit [Policy Text Block]	Restricted cash -
Prepaid Expenses and Other Current Assets [Policy Text Block]	Prepaid Expenses and Other Current Assets –
Property, Plant and Equipment, Policy [Policy Text Block]	Property and equipment, net – Years Computers, peripheral, and scientific equipment 3 Office furniture and equipment 4
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Long-Lived Assets
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	Patent Acquisition Costs – 22 The Company expenses costs associated with maintaining and defending patents subsequent to their issuance in the period incurred.
Accrued Expenses [Policy Text Block]	Accrued Expenses
Research and Development Expense, Policy [Policy Text Block]	Research and Development Expenses –
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation Expense –
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk –
Income Tax, Policy [Policy Text Block]	Income Taxes
Income Tax Uncertainties, Policy [Policy Text Block]	Uncertain Tax Positions –
Earnings Per Share, Policy [Policy Text Block]	Earnings Per Share earnings (loss) per common share is computed by dividing net income (loss) available to common shareholders by the sum of (1) the weighted-average number of Ordinary Shares outstanding during the period, (2) the dilutive effect of the assumed exercise of options and warrants using the treasury stock method and (3) the dilutive effect of other potentially dilutive securities.
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Income (Loss) – Balance January 1, 2016 $ 156,480 Net current period other comprehensive loss (348,353) Balance June 30, 2016 $ (191,873)
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers” (“ASU 2014-09”), which supersedes nearly all existing revenue recognition guidance under GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing GAAP. On July 9, 2015, the FASB voted to defer the effective date by one year to December 15, 2017 for interim and annual reporting periods beginning after that date. Early adoption of ASU 2014-09 is permitted but not before the original effective date (annual periods beginning after December 15, 2016). When effective, ASU 2014-09 prescribes either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients; or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). We are currently evaluating the impact of our pending adoption of ASU 2014-09 on our condensed consolidated financial statements and have not yet determined the method by which we will adopt the standard. In February 2016, the FASB issued ASU No. 2016-02, Leases In March 2016, the FASB issued ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting

Summary of Significant Accoun15

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2016
Significant Accounting Policies [Line Items]
Schedule of Rate of Depreciation of Property, Plant and Equipment [Table Text Block]	Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates: Years Computers, peripheral, and scientific equipment 3 Office furniture and equipment 4
Comprehensive Income (Loss) [Table Text Block]	The following table provides details with respect to changes in accumulated other comprehensive (loss) income (AOCI), which is comprised of foreign currency translation adjustments, as presented in the balance sheets for the six months ended June 30, 2016: Balance January 1, 2016 $ 156,480 Net current period other comprehensive loss (348,353) Balance June 30, 2016 $ (191,873)

Reverse Acquisition (Tables)

Reverse Acquisition (Tables)	6 Months Ended
	Jun. 30, 2016
Business Combinations [Abstract]
Schedule of Business Combination Purchase Price Allocation [Table Text Block]	The purchase price for Celsus on September 18, 2015, the closing date of the Acquisition, was as follows: Fair value of Celsus Ordinary Shares outstanding $ 20,034,625 (a) Fair value of Celsus share options 277,461 (2,516,690 options) Fair value of Celsus warrants 27,054 (1,782,246 warrants) Total purchase price $ 20,339,140 (a) computed by multiplying 55,636,283 Ordinary Shares of Celsus at Acquisition by the closing price on September 18, 2015, of $0.3601.
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	The following table summarizes the allocation of the purchase consideration to the assets acquired and liabilities assumed based on their fair values as of September 18, 2015: Cash and cash equivalents $ 1,410,577 Restricted cash 142,079 Prepaid expenses and other assets acquired 1,672,028 Excess consideration 19,283,280 Liabilities related to options and warrants (1,800,154) Other assumed liabilities (368,670) Total $ 20,339,140

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2016
Class of Stock [Line Items]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. June 30, 2016 December 31, 2015 Carrying Fair Carrying Fair Fair Amount Value Amount Value Value $ $ $ $ Levels Liability related to RPC options 14,616,664 14,616,664 15,711,017 15,711,017 3 Liability related to warrants 98,707 98,707 685,141 685,141 3
Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]	June 30 December 31, 2016 2015 Fair value measurements using input type Level 3 Warrants $ 98,707 $ 685,141 RPC options 14,616,664 15,711,017 Liabilities related to stock options and warrants $ 14,715,371 $ 16,396,158
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Fair value measurements using significant unobservable inputs (Level 3): Fair value of liabilities related to stock options and warrants Balance at December 31, 2015 $ 16,396,158 Changes in values of liability related to options and warrants (1,680,787) Balance at June 30, 2016 $ 14,715,371
Warrant [Member]
Class of Stock [Line Items]
Fair Value, by Balance Sheet Grouping [Table Text Block]	The fair value of warrants granted was measured using the Binomial method of valuation. Fair values were estimated using the following assumptions for the warrants as of June 30, 2016: Expected dividend yield 0 % Expected volatility 64.5 % Risk-free interest 0.41 % Expected life 0.76 years

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2016
Stockholders' Equity Note [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Weighted average Weighted Weighted remaining average average contractual Aggregate Number exercise grant date term intrinsic of shares price fair value (in years) value Options outstanding as of January 1, 2016 61,362,198 $ 0.34 9.7 $ - Changes during the period: Granted 20,100,000 $ 0.15 $ 0.10 Forfeited (4,533,334) $ 0.18 $ 0.11 Options outstanding as of June 30, 2016 76,928,864 $ 0.30 9.3 $ - Exercisable options as of June 30, 2016 12,797,676 $ 0.42 9.0 $ -
Schedule of Nonvested Share Activity [Table Text Block]	The following is a summary of the Company’s non-vested share options as of June 30, 2016 and changes during the six months ended June 30, 2016: Weighted average Number grant date of shares fair value Non-vested options as of December 31, 2015 58,480,181 $ 0.21 Options granted 20,100,000 $ 0.10 Options vested (9,915,659) $ 0.21 Non-vested options forfeited (4,533,334) $ 0.11 Non-vested as of June 30, 2016 64,131,188 $ 0.21
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	June 30, 2016 Expected dividend yield 0 % Expected volatility 74.18%-80.71 % Risk-free interest 1.03%-1.52 % Expected life 5.5-6.25 years
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	The following is a summary of the Company’s share options granted separated into ranges of exercise price: Remaining Options Weighted Options contractual outstanding average Weighted exercisable life (years Weighted Exercise as of remaining average as of for average price June contractual exercise June exercisable exercise (range) 30, 2016 life (years) price 30, 2016 options) price $ $ $ 0.14-0.19 21,713,351 9.76 0.16 1,627,185 9.38 0.19 0.32 53,597,347 9.22 0.32 9,915,659 9.22 0.32 0.60-0.75 380,000 7.73 0.71 380,000 7.73 0.71 1.15-1.56 311,500 3.74 1.35 311,500 3.74 1.35 2.00 926,666 7.23 2.00 563,332 7.24 2.00 76,928,864 12,797,676
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	The warrants outstanding as of June 30, 2016 are as follows: Number of Exercise Grant date warrants Price Expiration date 2012 warrants 1,383,086 $ 1.72 - $2.25 January 16, 2017-November 30, 2017 2013 warrants 399,160 $ 2.00 January 16, 2018-September 17, 2018 1,782,246

Earnings Per Share (Tables)

Earnings Per Share (Tables)	6 Months Ended
	Jun. 30, 2016
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Six Months Ended June 30, Earnings per share 2016 2015 Company posted Net loss Net loss Basic weighted average shares outstanding 1,177,693,383 722,345,600 Dilutive effect of Ordinary Share equivalents None None Dilutive weighted average shares outstanding 1,177,693,383 722,345,600
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Six-Month Six-Month Period Ended Period Ended June 30, 2016 June 30, 2015 Total share options 76,928,864 - Total warrants-equity classified 1,782,246 - Total warrants-liability classified 5,806,280 - Total share options and warrants 84,517,390 -

Nature of Business (Details Tex

Nature of Business (Details Textual)	1 Months Ended			6 Months Ended
	Sep. 18, 2015USD ($)$ / sharesshares	Oct. 23, 2013USD ($)	Oct. 23, 2013GBP (£)	Jun. 30, 2016shares	Sep. 18, 2015£ / shares
Nature Of Business [Line Items]
American Depositary Shares Description				each representing 100
Percentage Of Total Shares Issued	92.85%				92.85%
Percentage Of Total Shares Issued On Diluted Basis	91.68%				91.68%
Private Placement [Member]
Nature Of Business [Line Items]
Stock Issued During Period, Shares, New Issues	395,881,100
Stock Issued During Period, Value, New Issues | $	$ 75,000,000
Sale of Stock, Price Per Share | $ / shares	$ 0.18945
Sale of Stock, Percentage of Ownership after Transaction	33.30%
Private Placement [Member] | American Depositary Share [Member]
Nature Of Business [Line Items]
Stock Issued During Period, Shares, New Issues	3,958,811
Sale of Stock, Price Per Share | $ / shares	$ 18.945
RPC Pharma Limited [Member]
Nature Of Business [Line Items]
Shares Issued, Price Per Share | £ / shares					£ 0.01
Stock Issued During Period, Shares, Acquisitions	55,636,283			722,345,600
Volution [Member] | Patents [Member]
Nature Of Business [Line Items]
Payments to Acquire Intangible Assets		$ 107,000	£ 65,000

Summary of Significant Accoun21

Summary of Significant Accounting Policies (Details)	6 Months Ended
	Jun. 30, 2016
Computers, peripheral, and scientific equipment [Member]
Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Office furniture and equipment [Member]
Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life	4 years

Summary of Significant Accoun22

Summary of Significant Accounting Policies (Details 1)	6 Months Ended
	Jun. 30, 2016USD ($)
Significant Accounting Policies [Line Items]
Beginning Balance	$ 156,480
Net current period other comprehensive loss	(348,353)
Ending Balance	$ (191,873)

Summary of Significant Accoun23

Summary of Significant Accounting Policies (Details Textual)	6 Months Ended
	Jun. 30, 2016
Patents [Member]
Significant Accounting Policies [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period	22 years

Reverse Acquisition (Details)

Reverse Acquisition (Details) - USD ($)		1 Months Ended
		Sep. 18, 2015	Jun. 30, 2016
Business Combination [Line Items]
Total purchase price		$ 20,339,140
Options		2,516,690
Warrants		1,782,246	1,782,246
Fair value of Celsus share options [Member]
Business Combination [Line Items]
Total purchase price		$ 277,461
Fair value of Celsus Ordinary Shares outstanding [Member]
Business Combination [Line Items]
Total purchase price	[1]	20,034,625
Fair value of Celsus warrants [Member]
Business Combination [Line Items]
Total purchase price		$ 27,054
[1]	computed by multiplying 55,636,283 Ordinary Shares of Celsus at Acquisition by the closing price on September 18, 2015, of $0.3601.

Reverse Acquisition (Details 1)

Reverse Acquisition (Details 1)	Sep. 18, 2015USD ($)
Business Combination [Line Items]
Cash and cash equivalents	$ 1,410,577
Restricted cash	142,079
Prepaid expenses and other assets acquired	1,672,028
Excess consideration	19,283,280
Liabilities related to options and warrants	(1,800,154)
Other assumed liabilities	(368,670)
Total	$ 20,339,140

Reverse Acquisition (Details Te

Reverse Acquisition (Details Textual) - $ / shares	1 Months Ended	6 Months Ended
	Sep. 18, 2015	Jun. 30, 2016	Dec. 31, 2015
Business Combination [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired		91.68%
Common Stock, Shares, Outstanding		1,177,693,383	1,177,693,383
RPC Pharma Limited [Member]
Business Combination [Line Items]
Stock Issued During Period, Shares, Acquisitions	55,636,283	722,345,600
Celcus [Member]
Business Combination [Line Items]
Common Stock, Shares, Outstanding	55,636,283
Business Acquisition, Share Price	$ 0.3601

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Liabilities	$ 17,049,165	$ 21,174,037
Fair Value, Inputs, Level 3 [Member] | Liability related to RPC options [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial Liabilities Fair Value Disclosure	14,616,664	15,711,017
Liabilities	14,616,664	15,711,017
Fair Value, Inputs, Level 3 [Member] | Liability related to warrants [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial Liabilities Fair Value Disclosure	98,707	685,141
Liabilities	$ 98,707	$ 685,141

Fair Value Measurements (Deta28

Fair Value Measurements (Details 1) - Employee Stock Option [Member]	6 Months Ended
	Jun. 30, 2016
Class of Stock [Line Items]
Expected dividend yield	0.00%
Expected volatility	64.50%
Risk-free interest	0.41%
Expected life	9 months 4 days

Fair Value Measurements (Deta29

Fair Value Measurements (Details 2) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Stock Options And Warrants Fair Value Disclosure	$ 14,616,664
RPC Pharma Ltd [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Stock Options And Warrants Fair Value Disclosure	1,094,353	$ 15,711,017
Fair Value, Inputs, Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Stock Options And Warrants Fair Value Disclosure	14,715,371	16,396,158
Fair Value, Inputs, Level 3 [Member] | Warrant [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Stock Options And Warrants Fair Value Disclosure	98,707	685,141
Fair Value, Inputs, Level 3 [Member] | RPC Pharma Ltd [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Stock Options And Warrants Fair Value Disclosure	$ 14,616,664	$ 15,711,017

Fair Value Measurements (Deta30

Fair Value Measurements (Details 3) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Changes in values of liabilities related to options and warrants	$ (976,452)	$ 0	$ (1,680,787)	$ 0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Balance			16,396,158
Changes in values of liabilities related to options and warrants			(1,680,787)
Balance	$ 14,715,371		$ 14,715,371

Fair Value Measurements (Deta31

Fair Value Measurements (Details Textual) - USD ($)	1 Months Ended		6 Months Ended	12 Months Ended
	Sep. 30, 2015	Jul. 31, 2015	Jun. 30, 2016	Dec. 31, 2015
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award			5,806,280
Warrant Issuance Exercise Price Description			share or warrant issuance at less than $0.18945 price share or exercise price per share
Liability Related To Stock Options and Warrants			$ 14,715,371	$ 16,396,158
Stock Options And Warrants Fair Value Disclosure			14,616,664
Debt Instrument, Unamortized Discount	$ 3,000,000
Interest Expense, Other	3,000,000
Financing Interest Expense				23,000,000
Derivative Liability, Fair Value, Gross Liability			586,434	685,141
Warrant [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability, Fair Value, Gross Liability			98,707
RPC Pharma Ltd [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Percentage Of Shares Outstanding		15.00%
Liability Related To Stock Options and Warrants	$ 26,000,000
Stock Options And Warrants Fair Value Disclosure			$ 1,094,353	$ 15,711,017
Short-term Debt		$ 3,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value		$ 26,000,000
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners		15.00%

Shareholders' Equity (Details)

Shareholders' Equity (Details) - USD ($)	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Class of Stock [Line Items]
Number of shares, Options outstanding at end of the period	76,928,864
Number of shares, Options exercisable at end of the period	12,797,676
Employee Stock Option [Member]
Class of Stock [Line Items]
Number of shares, Outstanding at beginning of the period	61,362,198
Number of shares, Granted	20,100,000
Number of shares, Forfeited	(4,533,334)
Number of shares, Options outstanding at end of the period	76,928,864
Number of shares, Options exercisable at end of the period	12,797,676
Weighted average exercise price, Outstanding at beginning of the period	$ 0.34
Weighted average exercise price, Granted	0.15
Weighted average exercise price, Forfeited	0.18
Weighted average exercise price,outstanding at end of the period	0.3
Options exercisable at end of the period, Weighted average exercise price	0.42
Weighted average grant date fair value Granted	0.1
Weighted average grant date fair value Forfeited	$ 0.11
Weighted average remaining contractual term, Options outstanding during the period (in years)	9 years 3 months 18 days
Weighted average remaining contractual term, Options exercisable at end of the period (in years)	9 years	9 years 8 months 12 days
Aggregate intrinsic value, Options outstanding at beginning of the period		$ 0
Aggregate intrinsic value, Options outstanding at end of the period	$ 0
Aggregate intrinsic value, Options exercisable at end of the period	$ 0

Shareholders' Equity (Details 1

Shareholders' Equity (Details 1) - $ / shares	1 Months Ended	6 Months Ended
	Sep. 18, 2015	Jun. 30, 2016
Number of Shares
Non-vested options Vested	(2,516,690)
Employee Stock Option [Member]
Number of Shares
Non-vested options granted		20,100,000
Non-vested options Vested		(9,915,659)
Non-vested options forfeited		(4,533,334)
Weighted average grant date fair value
Non-vested options granted		$ 0.1
Non-vested options Vested		0.21
Non-vested options forfeited		$ 0.11
Nonvested Option [Member]
Number of Shares
Non-vested options at December 31, 2015		58,480,181
Non-vested at June 30, 2016		64,131,188
Weighted average grant date fair value
Non-vested options at December 31, 2015		$ 0.21
Non-vested at June 30, 2016		$ 0.21

Shareholders' Equity (Details 2

Shareholders' Equity (Details 2) - Call Option [Member]	6 Months Ended
	Jun. 30, 2016
Class of Stock [Line Items]
Expected dividend yield	0.00%
Minimum [Member]
Class of Stock [Line Items]
Expected volatility	74.18%
Risk-free interest	1.03%
Expected life	5 years 6 months
Maximum [Member]
Class of Stock [Line Items]
Expected volatility	80.71%
Risk-free interest	1.52%
Expected life	6 years 3 months

Shareholders' Equity (Details 3

Shareholders' Equity (Details 3)	6 Months Ended
	Jun. 30, 2016$ / sharesshares
Class of Stock [Line Items]
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Number | shares	76,928,864
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Number | shares	12,797,676
Exercise Price Range One [Member]
Class of Stock [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	$ 0.14
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	$ 0.19
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Number | shares	21,713,351
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	9 years 9 months 4 days
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 0.16
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Number | shares	1,627,185
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	9 years 4 months 17 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 0.19
Exercise Price Range Two [Member]
Class of Stock [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	$ 0.32
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Number | shares	53,597,347
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	9 years 2 months 19 days
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 0.32
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Number | shares	9,915,659
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	9 years 2 months 19 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 0.32
Exercise Price Range Three [Member]
Class of Stock [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	0.60
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	$ 0.75
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Number | shares	380,000
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	7 years 8 months 23 days
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 0.71
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Number | shares	380,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	7 years 8 months 23 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 0.71
Exercise Price Range Four [Member]
Class of Stock [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	1.15
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	$ 1.56
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Number | shares	311,500
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	3 years 8 months 26 days
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 1.35
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Number | shares	311,500
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	3 years 8 months 26 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 1.35
Exercise Price Range Five [Member]
Class of Stock [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	$ 2
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Number | shares	926,666
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	7 years 2 months 23 days
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 2
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Number | shares	563,332
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	7 years 2 months 26 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 2

Shareholders' Equity (Details 4

Shareholders' Equity (Details 4) - $ / shares	6 Months Ended
	Jun. 30, 2016	Sep. 18, 2015
Class of Stock [Line Items]
Number of warrants	1,782,246	1,782,246
Warrants 2012 [Member]
Class of Stock [Line Items]
Number of warrants	1,383,086
Warrants 2012 [Member] | Maximum [Member]
Class of Stock [Line Items]
Exercise Price	$ 2.25
Expiration date	Nov. 30, 2017
Warrants 2012 [Member] | Minimum [Member]
Class of Stock [Line Items]
Exercise Price	$ 1.72
Expiration date	Jan. 16, 2017
Warrants 2013 [Member]
Class of Stock [Line Items]
Number of warrants	399,160
Exercise Price	$ 2
Warrants 2013 [Member] | Maximum [Member]
Class of Stock [Line Items]
Expiration date	Sep. 17, 2018
Warrants 2013 [Member] | Minimum [Member]
Class of Stock [Line Items]
Expiration date	Jan. 16, 2018

Shareholders' Equity (Details T

Shareholders' Equity (Details Textual) - USD ($)	1 Months Ended				6 Months Ended
	Jun. 29, 2016	Apr. 22, 2016	Mar. 23, 2016	Sep. 18, 2015	Jun. 30, 2016	Jul. 29, 2016	Dec. 31, 2015
Class of Stock [Line Items]
Common Stock, Shares Authorized					5,000,000,000		5,000,000,000
Common Stock, Shares, Outstanding					1,177,693,383		1,177,693,383
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares				2,516,690
Non Employee [Member]
Class of Stock [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized					$ 11,057,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition					3 years 2 months 12 days
Employees And Directors [Member]
Class of Stock [Line Items]
Stock Issued During Period, Value, Share-based Compensation, Gross					$ 1,622,000
Director [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	7,800,000	1,300,000
Weighted average exercise price, Granted	$ 0.145	$ 0.18
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares	6,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Beginning Balance						1,300,000
Private Placement [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues				395,881,100
Stock Issued During Period, Value, New Issues				$ 75,000,000
Sale of Stock, Price Per Share				$ 0.18945
Employee Stock [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			11,000,000
Weighted average exercise price, Granted			$ 0.141
RPC Pharma Limited [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Acquisitions				55,636,283	722,345,600
MTS Health Partners [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Issued for Services				3,830,400
Stock Issued During Period, Value, Issued for Services				$ 750,000
Business Combination, Integration Related Costs				$ 500,000
2014 Equity Incentive Plan [Member]
Class of Stock [Line Items]
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period					141,142,420
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized					64,213,556

Related Party Transactions (Det

Related Party Transactions (Details Textual) - USD ($)	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Related Party Transaction [Line Items]
Related Party Transaction, Amounts of Transaction	$ 23,000	$ 71,000
Accounts Receivable, Related Parties, Current	$ 10,502		$ 10,366

Earnings Per Share (Details)

Earnings Per Share (Details) - shares	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Earnings Per Share [Line Items]
Basic weighted average shares outstanding	1,177,693,383	722,345,600
Dilutive weighted average shares outstanding	1,177,693,383	722,345,600

Earnings Per Share (Details 1)

Earnings Per Share (Details 1) - shares	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Earnings Per Share [Line Items]
Total stock options and warrants	84,517,390	0
Stock Options [Member]
Earnings Per Share [Line Items]
Total stock options and warrants	76,928,864	0
Warrants Equity Classified [Member]
Earnings Per Share [Line Items]
Total stock options and warrants	1,782,246	0
Warrants Liability Classified [Member]
Earnings Per Share [Line Items]
Total stock options and warrants	5,806,280	0